Ozempic could be the next target of Medicare drug price negotiations – here’s why

Wall Street analysts expect Ozempic to be selected for price negotiations in 2025 due to the amount of money Medicare Part D already spends on the drug…
Read More

By admin

0 0 votes
Article Rating
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x